Chronic Granulomatous Disease (CGD) is a rare genetic disorder that affects the immune system, specifically the ability of phagocytes to produce reactive oxygen species (ROS) necessary for ...
In a Phase I/II trial, patients with X-linked chronic granulomatous disease will receive a treatment created using a new ...
Odyssey Therapeutics Inc. has reported new receptor-interacting serine/threonine-protein kinase 2 (RIPK2; RIP-2) inhibitors described as potentially useful for the treatment of autoimmune diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback